Objective To explore the clinical effect of Xingpi Quyu Tongmai decoction combined with betahistine mesylate in the treatment of benign paroxysmal positional vertigo. Methods A total of 60 patients with benign paroxysmal positional vertigo treated in a hospital in Henan Province from November 2018 to December 2020 were randomly divided into control group and observation group

with 30 cases in each group. Patients in the control group were treated with betastine mesylate tablets

and observation group were treated with Xingpi Quyu Tongmai decoction on the basis of the control group. The clinical efficacy

TCM syndrome score and dizziness handicap inventory（DHI） before and after treatment were compared between the two groups. Results The total effective rate of the observation group was 96.67%

which was higher than that of the control group（73.33%）

and the difference was statistically significant（P<0.05）. Before treatment

there was no significant difference in TCM syndrome scores between the two groups（P>0.05）. After treatment

the syndrome scores of visual rotation

head weight

nausea

vomiting and chest tightness in the two groups were lower than those before treatment; and those in the observation group were lower than those in the control group; the difference was statistically significant（P<0.05）. Before treatment

there was no significant difference in the degree of vertigo between the two groups（P>0.05）. After treatment

the scores and total scores of body

emotion and function in the DHI among the two groups were lower than those before treatment; and those in the observation group were lower than those in the control group; the difference was statistically significant（P<0.05）. Conclusion Xingpi Quyu Tongmai decoction combined with betahistine mesylate tablets is effective in the treatment of benign paroxysmal positional vertigo

and could help to promote the elimination of symptoms and signs

which is worth popularizing.